Floaria Bicher/iStock via Getty Images Arcellx, Inc. (NASDAQ:ACLX) is a biotechnology company with innovative oncology CAR-T cell therapies. ACLX leverages proprietary platforms, including D-Domain, ddCAR, and ARC-SparX, to enhance the immune system's capabilities to detect and kill cancer cells. Currently, ACLX’s leading product candidate is anitocabtagene autoleucel [anito-cel], which shows promising results in patients with relapsed/refractory multiple myeloma [r/r MM]. These results seem to also hol ...

Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.50 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 5.56%. A quarter ago, it was expected that this company would post a loss of $0.51 per share when it actually produced a loss of $0.14, delivering a surprise of 72.55%.Over the last four quarters, the company has surpassed c ...

公司概况 - 公司主要从事创新细胞治疗的临床阶段生物技术公司[76] - 公司正在开发靶向BCMA的ddCAR产品候选药物anito-cel，正在进行关键性II期临床试验[77] - 公司还在开发两个临床阶段的ARC-SparX项目，分别针对BCMA和CD123[78] 财务情况 - 公司预计未来运营费用和资本需求将大幅增加，以支持产品候选药物的持续开发[79][80] - 公司目前的现金和现金等价物以及可供出售的证券足以为运营提供资金支持到2027年[82] - 公司与Kite的合作关系中获得了6830万美元的临床里程碑付款[83] - 合作收入为27.4百万美元，较2023年同期增加13.1百万美元[99] - 研发费用为41.0百万美元，较2023年同期增加12.6百万美元，主要由于其他临床前管线项目成本增加5.9百万美元以及内部成本增加5.5百万美元[101][102] - 一般及行政费用为21.4百万美元，较2023年同期增加5.9百万美元，主要由于人员相关成本增加3.8百万美元[103] - 其他收益净额为8.1百万美元，较2023年同期增加2.7百万美元，主要由于现金及现金等价物和可供出售证券余额增加带来的利息收入增加[104] - 合作收入为66.6百万美元，较2023年同期增加34.4百万美元，主要由于Kite合作协议修订带来的交易价格估计增加[107] - 研发费用为73.3百万美元，较2023年同期增加12.0百万美元，主要由于内部成本增加9.2百万美元以及其他临床前管线项目成本增加7.9百万美元[108][109] - 一般及行政费用为44.2百万美元，较2023年同期增加13.2百万美元，主要由于人员相关成本增加8.2百万美元[110] - 其他收益净额为16.7百万美元，较2023年同期增加7.9百万美元，主要由于现金及现金等价物和可供出售证券余额增加带来的利息收入增加[111] - 截至2024年6月30日，公司现金及现金等价物和可供出售证券余额为646.8百万美元[112] - 预计目前现金及现金等价物和可供出售证券余额可为公司运营提供资金支持至2027年[114] 市场风险 - 公司拥有6.468亿美元的现金、现金等价物和有价证券投资，主要投资于美国政府机构证券和国债、存单和货币市场账户[126] - 公司主要面临利率变动带来的市场风险，因为其投资主要集中在短期证券[126] - 公司的可供出售证券会受到市场利率上升的影响而贬值[126] - 公司已在年度报告中讨论了这类市场风险的敏感性分析[126] - 从上一年年底至2024年6月30日,这方面的信息没有发生重大变化[126]

临床试验进展 - 公司获得了来自Kite的6800万美元里程碑付款,用于iMMagine-1试验的入组[4] - 公司已向第66届ASH年会提交了iMMagine-1研究的摘要[4] - Kite已启动全球III期试验iMMagine-3,用于评估anito-cel在曾接受免疫调节药物和抗CD38单抗治疗的多发性骨髓瘤患者中的疗效[5] - FDA已批准公司针对重症肌无力这一自身免疫性疾病开发anito-cel的IND申请[5] 财务状况 - 截至2024年6月30日,公司拥有6.468亿美元的现金、现金等价物和可流动性证券,预计可为公司运营提供资金支持至2027年[6] - 2024年第二季度,公司的合作收入为2740万美元,同比增长13.1百万美元,主要由于与Kite的许可和合作协议扩展所致[7] - 2024年第二季度,公司的研发费用为4100万美元,同比增加1270万美元,主要由于其他临床前管线项目成本和人员成本(包括股份支付)的增加[8] - 2024年第二季度,公司的管理费用为2140万美元,同比增加590万美元,主要由于人员成本(包括股份支付)的增加[9]

Nemes Laszlo/iStock via Getty Images Arcellx’s Anito-cel: A Promising Contender in Multiple Myeloma Therapy Arcellx (NASDAQ:ACLX) is developing cell therapies for multiple myeloma [MM], acute myeloid leukemia, and myelodysplastic syndrome. Anito-cel (formerly CART-ddBCMA), the company's flagship product, is being developed in a Phase 2 pivotal trial for relapsed or refractory MM (rrMM). My last article on Arcellx was in September, a month after the FDA lifted the partial clinical hold (limits some trial asp ...

Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.58 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 72.55%. A quarter ago, it was expected that this company would post a loss of $0.63 per share when it actually produced earnings of $0.42, delivering a surprise of 166.67%. Over the last four quarters, the company has surpa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-41259 ARCELLX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-2855917 (State or other jurisd ...

Exhibit 99.1 Arcellx Provides First Quarter 2024 Financial Results REDWOOD CITY, Calif., May 9, 2024 (BUSINESS WIRE) — Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights Cash, cash equivalents, and marketable securities: As of March 3 ...

Biotech breakthrough stocks, along with the sector overall, faced significant challenges over the past two years, with venture capital drying up, shifts in the post-pandemic healthcare landscape and tighter regulatory conditions squeezing already-thin margins. However, 2024 may herald a resurgence for biotech stocks, spurred by an FDA approval spree throughout 2023. Last year, the FDA approved 55 treatment protocols that included previously unapproved ingredients or compounds, a significant increase from th ...

公司盈利预期 - Arcellx 公司近期看起来也不错，过去一个月内盈利预期有所改善[3] - 公司当前的盈利预期已经有所缩小，Zacks Rank 3 (Hold) 也是一个积极信号[4] 行业趋势 - 医疗 - 生物医学和遗传学行业整体上升，对公司股票有利[2] 公司概况 - Arcellx, Inc. (ACLX) 是医疗 - 生物医学和遗传学领域的一个有趣选择[1]